Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)

BackgroundIntratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin and nivolumab may have synergistic effects in advanced sarcomas.Patients and methodsThis phase 2 trial was conducted from May 30, 2...

Full description

Bibliographic Details
Main Authors: Sant P. Chawla, Walter Andree Tellez, Hripsime Chomoyan, Chrysler Valencia, Amir Ahari, Nadezhda Omelchenko, Stefan Makrievski, Don A. Brigham, Victoria Chua-Alcala, Doris Quon, Ania Moradkhani, Erlinda M. Gordon
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
talimogene laherparepvec
nivolumab
trabectedin
sarcoma
immunotherapy
alkylating agents
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1116937/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1116937/full

Similar Items